Amgen's Q1 results reflect a slight decline in overall product sales; however, the increase in EPS and the raised revenue guidance indicate strong performance from newer products like Repatha and Aimovig, alongside growth in biosimilars. Management's optimistic outlook and strategic investments suggest confidence in overcoming short-term challenges, likely fostering a positive reaction in the stock market.

[1]